undamentalytics Newsletter
Sign in

Werewolf Therapeutics, Inc. (HOWL) stock

Add to watchlist

Add holding +

NASDAQ: HOWL Nasdaq Biotechnology Next results ~November 3, 2026

Werewolf Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 12 selling0 purchases and 148 sales by directors and officers, last 12 monthsInsider trades
  • Funds18 adding, 21 cuttingOf 9 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 145% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 142% and a beta of 2.0 against the S&P 500.
  • Short interest rising. Shares sold short rose 38% in a month to 5.9% of tradable shares.

Latest results

Earnings per share
$0.14 against an average estimate of -$0.32: beat by 145.2%
Share reaction
-26.4% in the first session after the results on July 31, 2026, against +2.2% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.22

Werewolf Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+6.5%
  • 1 week+7.0%
  • 1 month+13.1%
  • This year+65.6%
  • 1 year-19.8%
  • 5 years-93.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
July 31, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Agreement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Werewolf Therapeutics, Inc. valuation models and calculator

No model value for Werewolf Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Werewolf Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.17 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Werewolf Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect EPS of −$0.22 (range −$0.22 to −$0.22) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.89 +33% — 0%
Next −$0.59 +34% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is 0.0% on 90 days ago. In the last 30 days, 1 analyst raised Werewolf Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Werewolf Therapeutics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.89 Current fiscal year, 30 days ago: −$1.27 Current fiscal year, 7 days ago: −$1.27 Current fiscal year, Now: −$0.89 −$0.89

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$0.89
30 days ago −$1.27
7 days ago −$1.27
Now −$0.89

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.32 $0.14 +145.2%
Mar 2026 −$0.29 −$0.28 +5.1%
Dec 2025 −$0.35 −$0.17 +51.0%
Sept 2025 −$0.38 −$0.36 +5.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
5.9%
of tradable shares
Days to cover
3.83
at average volume
Short interest, 1 month
+38%
to October 15, 2026
Held by institutions
40%
of shares
Held by insiders
6.6%
of shares
Employees
39
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
HOWL−83%+88%−62%−57%+66%
Industry peers (median)−56%−18%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
HOWL42%42%25%33%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
HOWL−88%−59%−81%−72%−70%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 30, 2021: 99% from July 2, 2021 to June 29, 2026. Getting back needed a 6494% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.31 – $1.31
From 52-week high
−19.8%
vs 50-day average
+8.1%
vs 200-day average
+53.5%
Volatility (1 year)
143%
Beta vs S&P 500
2.01

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±7.2%
After a week
4 up, 8 down
typical move ±14.8%
After a month
5 up, 7 down
typical move ±34.1%
Results releasedNext dayS&P 500 next day5 days21 days
July 31, 2026 −26.4% +2.2% −20.6% +88.2%
May 7, 2026 +4.6% +0.5% −16.5% −41.2%
March 27, 2026 −7.6% −2.0% +20.5% −14.3%
November 4, 2025 −6.9% −0.8% −13.7% −24.0%
August 14, 2025 −1.5% −0.2% −5.2% +5.9%
May 8, 2025 −13.1% +0.6% +20.5% +53.1%
March 11, 2025 +0.4% −0.3% −5.3% −41.2%
November 7, 2024 −5.7% +1.2% −20.9% −24.2%
August 8, 2024 +10.5% +2.8% +18.1% +24.6%
May 3, 2024 −1.6% +2.3% −16.9% −40.1%
March 7, 2024 −7.4% +0.4% −13.1% −23.5%
November 14, 2023 −0.9% +2.2% +6.8% +28.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$3.9M
Institutions reporting
45
Shares held vs prior quarter
▼ 22.4%
Positions opened / closed
9 / 12

Top buyers and sellers, Q2 2026: 18 institutions bought and 21 sold ; the biggest buyer was Balyasny Asset Management L.P (+1.8M shares) and the biggest seller RA Capital Management, L.P (−4.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $859,349 2.4M 22.0% ▼ 64.3%
Balyasny Asset Management L.P. $644,253 1.8M 16.5% New
Vanguard Capital Management LLC $438,471 1.2M 11.2% 0.0%
Renaissance Technologies LLC $242,800 675K 6.2% ▲ 30.7%
Lynx1 Capital Management LP $236,737 658K 6.1% 0.0%
Sphera Funds Management Ltd. $225,589 627K 5.8% 0.0%
Dc Funds, LP $212,018 589K 5.4% 0.0%
Verdad Advisers, LP $125,500 349K 3.2% ▲ 1071.7%
Geode Capital Management, LLC $120,895 336K 3.1% ▼ 13.8%
Bank Of America Corp $111,829 312K 2.9% ▲ 17.7%
Xtx Topco Ltd $97,705 271K 2.5% ▲ 433.1%
Jane Street Group, LLC $90,637 252K 2.3% ▲ 204.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Werewolf Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $6.8M 148 trades by 12 insiders · 86% under pre-set plans
Net ▼ $6.8M net selling
Insider Date Trade Shares Price Value
Evnin Luke Director July 7, 2026 Sell pre-set plan 107,429 $0.31 $33,303
Evnin Luke Director July 6, 2026 Sell pre-set plan 35,770 $0.32 $11,446
Evnin Luke Director June 29, 2026 Sell pre-set plan 157,084 $0.30 $47,125
Ra Capital Management, L.P. 10% owner June 17, 2026 Sell 27,695 $0.35 $9,693
Ra Capital Management, L.P. 10% owner June 17, 2026 Sell 389,216 $0.35 $136,226
Ra Capital Management, L.P. 10% owner June 16, 2026 Sell 9,939 $0.37 $3,677
Ra Capital Management, L.P. 10% owner June 16, 2026 Sell 139,686 $0.37 $51,684
Ra Capital Management, L.P. 10% owner June 15, 2026 Sell 8,554 $0.39 $3,336
Ra Capital Management, L.P. 10% owner June 15, 2026 Sell 120,216 $0.39 $46,884
Ra Capital Management, L.P. 10% owner June 12, 2026 Sell 11,322 $0.40 $4,529
Ra Capital Management, L.P. 10% owner June 12, 2026 Sell 159,119 $0.40 $63,648
Kolchinsky Peter 10% owner June 11, 2026 Sell 245,066 $0.38 $93,125

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • July 31, 2026
  • May 7, 2026
  • March 27, 2026
  • November 4, 2025
  • August 14, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Werewolf Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Werewolf Therapeutics, Inc. in brief

What does Werewolf Therapeutics, Inc. do?
Werewolf Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Werewolf Therapeutics, Inc.'s stock ticker?
Werewolf Therapeutics, Inc. trades under the ticker HOWL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Werewolf Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Balyasny Asset Management L.P. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Werewolf Therapeutics, Inc. stock?
Over the last 12 months, Werewolf Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 148 sales on Form 4. The insider trading page charts every trade.
When is Werewolf Therapeutics, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Werewolf Therapeutics, Inc. announces its own schedule.